Physician profile
Min Xu
NPI 1922212471
$3,133.40
in general payments reported to CMS, 2019-2025
22 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2021: $237 · 2022: $162 · 2023: $490 · 2024: $675 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,433.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $415.90 | 2024-2025 | Erleada, Akeega, Rybrevant |
| Ferring Pharmaceuticals INC. | $389.66 | 2024-2025 | Adstiladrin |
| Medtronic, INC. | $383.42 | 2023-2025 | Interstim |
| Endo Pharmaceuticals INC. | $276.47 | 2019-2024 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $264.06 | 2024-2025 | |
| Astellas Pharma US INC | $260.18 | 2021-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $177.54 | 2023-2025 | Gemtesa |
| Telix Pharmaceuticals | $130.43 | 2023-2025 | Illuccix |
| Janssen Scientific Affairs, LLC | $122.93 | 2025 | |
| Abbvie INC. | $106.38 | 2019-2023 | Botox |
| Blue Earth Diagnostics | $94.15 | 2019 | |
| Myovant Sciences INC. | $90.50 | 2021 | |
| Boston Scientific Corporation | $85.43 | 2022-2023 | Rezum Generator |
| Progenics Pharmaceuticals, INC. | $83.46 | 2021-2023 | Pylarify |
| Endo USA, INC. | $73.62 | 2024-2025 | Xiaflex, Aveed |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $48.83 | 2024 | |
| Merck Sharp & Dohme LLC | $29.77 | 2024 | Keytruda |
| 180 Medical, INC. | $27.56 | 2023 | Gentlecath |
| Myriad Genetic Laboratories, INC. | $21.00 | 2024 | Myrisk |
| C. R. Bard, INC. & Subsidiaries | $19.93 | 2019 | |
| Pfizer INC. | $16.82 | 2019 | |
| Medtronic USA, INC. | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.